FLEURY S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.05 BRL | +0.29% |
|
-1.20% | -22.12% |
| May. 10 | Fleury Seeks Acquisitions | CI |
| May. 10 | Transcript : Fleury S.A., Q1 2024 Earnings Call, May 10, 2024 |
| Sales 2024 * | 7.8B 1.49B | Sales 2025 * | 8.35B 1.59B | Capitalization | 7.67B 1.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 627M 120M | Net income 2025 * | 774M 148M | EV / Sales 2024 * | 1.46 x |
| Net Debt 2024 * | 3.7B 706M | Net Debt 2025 * | 3.22B 615M | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
12.4
x | P/E ratio 2025 * |
10
x | Employees | 27,300 |
| Yield 2024 * |
5.24% | Yield 2025 * |
6.04% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | -0.64% | ||
| 1 week | -1.20% | ||
| 1 month | -2.97% | ||
| 3 months | -11.69% | ||
| 6 months | -18.17% | ||
| Current year | -22.12% |
1 week
13.86
14.56
1 month
13.8615.07
Current year
13.6918.08
1 year
13.6918.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 58 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 14 M€ | -4.02% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 14.05 | -0.64% | 2,592,800 |
| 24-05-29 | 14.14 | -2.48% | 2,414,500 |
| 24-05-28 | 14.5 | +1.33% | 2,937,000 |
| 24-05-27 | 14.31 | +0.63% | 1,254,600 |
| 24-05-24 | 14.22 | -0.42% | 1,371,300 |
Delayed Quote Sao Paulo, May 31, 2024 at 04:07 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
2024-06-04
- Bradesco BBI London Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
14.05
BRL
Average target price
19.33
BRL
Spread / Average Target
+37.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.12% | 1.46B | |
| -24.16% | 7.76B | |
| +68.65% | 4.33B | |
| -2.98% | 2.64B | |
| +2.72% | 2.63B | |
| -46.17% | 2.16B | |
| +13.62% | 1.17B | |
| -43.81% | 1.14B | |
| +20.41% | 999M | |
| -9.27% | 955M |
- Stock Market
- Equities
- FLRY3 Stock
